Upstream Bio's (UPB) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Key Points

• Upstream Bio's stock has been reaffirmed with a "Sell (D-)" rating by Weiss Ratings, despite Truist Financial recently initiating coverage with a "Buy" rating and a $47 price target.
• The company reported a loss of ($0.74) earnings per share in its last quarterly results, which missed analysts' expectations of ($0.61) by ($0.13).
• Upstream Bio experienced a stock price increase of 3.5%, trading at $21.86, while holding a 52-week low of $5.14 and a high of $29.46.

Upstream Bio (NASDAQ:UPB - Get Free Report)'s stock had its "sell (d-)" rating reissued by research analysts at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

Separately, Truist Financial assumed coverage on shares of Upstream Bio in a research report on Tuesday, October 14th. They set a "buy" rating and a $47.00 price target on the stock. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $53.33.

Upstream Bio Stock Up 3.5%

Shares of UPB stock traded up $0.73 on Friday, hitting $21.86. 186,192 shares of the stock were exchanged, compared to its average volume of 379,671. Upstream Bio has a fifty-two week low of $5.14 and a fifty-two week high of $29.46. The business has a 50-day moving average of $18.58 and a 200 day moving average of $13.56.

Upstream Bio (NASDAQ:UPB - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.13). Upstream Bio had a negative return on equity of 35.90% and a negative net margin of 3,836.58%.The firm had revenue of $0.94 million for the quarter, compared to analyst estimates of $0.32 million. On average, sell-side analysts anticipate that Upstream Bio will post -4.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its position in shares of Upstream Bio by 229.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company's stock worth $34,000 after acquiring an additional 2,158 shares in the last quarter. Bain Capital Life Sciences Investors LLC boosted its position in shares of Upstream Bio by 6.3% during the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 2,439,538 shares of the company's stock worth $26,786,000 after acquiring an additional 144,216 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Upstream Bio by 71.2% during the 2nd quarter. Bank of America Corp DE now owns 18,031 shares of the company's stock worth $198,000 after acquiring an additional 7,500 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Upstream Bio by 85.4% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,084 shares of the company's stock worth $210,000 after acquiring an additional 8,788 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Upstream Bio during the 2nd quarter worth approximately $145,000.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.